Takeda Pharmaceutical Company Limited (NYSE:TAK) Shares Sold by Brandes Investment Partners LP

Brandes Investment Partners LP lessened its stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) by 5.9% during the fourth quarter, Holdings Channel.com reports. The fund owned 3,039,585 shares of the company’s stock after selling 192,019 shares during the period. Brandes Investment Partners LP’s holdings in Takeda Pharmaceutical were worth $40,244,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in TAK. FMR LLC increased its stake in shares of Takeda Pharmaceutical by 10.9% during the third quarter. FMR LLC now owns 2,908,918 shares of the company’s stock valued at $41,365,000 after acquiring an additional 286,052 shares during the period. Stifel Financial Corp increased its stake in shares of Takeda Pharmaceutical by 103.9% during the third quarter. Stifel Financial Corp now owns 440,666 shares of the company’s stock valued at $6,266,000 after acquiring an additional 224,594 shares during the period. Crossmark Global Holdings Inc. increased its stake in shares of Takeda Pharmaceutical by 284.9% during the fourth quarter. Crossmark Global Holdings Inc. now owns 210,484 shares of the company’s stock valued at $2,787,000 after acquiring an additional 155,795 shares during the period. Raymond James Financial Inc. acquired a new position in shares of Takeda Pharmaceutical during the fourth quarter valued at approximately $1,447,000. Finally, Verition Fund Management LLC acquired a new position in shares of Takeda Pharmaceutical during the third quarter valued at approximately $1,533,000. Institutional investors and hedge funds own 9.17% of the company’s stock.

Takeda Pharmaceutical Trading Down 0.1 %

Takeda Pharmaceutical stock opened at $15.02 on Friday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.72 and a current ratio of 1.31. The firm has a market cap of $47.78 billion, a price-to-earnings ratio of 37.54, a price-to-earnings-growth ratio of 0.24 and a beta of 0.46. Takeda Pharmaceutical Company Limited has a 1 year low of $12.58 and a 1 year high of $15.22. The firm’s 50 day moving average price is $13.76 and its two-hundred day moving average price is $13.92.

Takeda Pharmaceutical (NYSE:TAK) last posted its quarterly earnings results on Thursday, January 30th. The company reported $0.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. On average, research analysts predict that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current fiscal year.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.